the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
March 31, 2019 – The American Food and Drug Administration (FDA) has just approved drugs for two rather problematic neurological conditions, namely multiple sclerosis (i.e., Cladribine (Mavenclad)) and non-radiographic axial spondyloarthritis (i.e., Certolizumab pegol (Cimzia)), offering patients with these conditions …
New treatments for multiple sclerosis and inflammatory arthritis approved Read more »
January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons. …
Febuxostat (Uloric) and its problem with cardiovascular mortality Read more »
November 16, 2017 – The American Food & Drug Administration (FDA) just approved Ability MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication. This is a very first in its class at the new age …
Abilify MyCite, the first digital pill. Where does all that silicone go? Read more »
October 19, 2017 – The American Food & Drug Administration (FDA) just approved Axicabtagene Ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed …
Axicabtagene Ciloleucel (Yescarta) gene therapy for diffuse large B-cell lymphoma Read more »
September 3, 2017 – For a very first time, the American Food & Drug Administration (FDA) has approved a gene therapy for the United States (US) in that it approved CAR T-cell therapy to treat certain children and young adults with …
August 02, 2017 – This is another cornerstone in the fight against acute myeloid leukemia (AML): The American Food and Drug Administration (FDA) just approved Enasidenib (Idhifa) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia …
Enasidenib (Idhifa): Targeted treatment for relapsed or refractory AML Read more »
February 16, 2017 – The American Food & Drug Administration (FDA) just approved Brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab (Siliq) is administered as an injection. Brodalumab (Siliq) is intended for patients who are candidates for systemic therapy (treatment …
Brodalumab (Siliq) with a fatal touch: New psoriasis drug approved Read more »
October 05, 2016 – Here, we make available to our readers a Drug Safety Communication by the American Food & Drug Administration (FDA), where FDA warns about the risk of hepatitis B virus (HBV) reactivation in some patients treated with …
September 01, 2016 – This is what we learned this morning and sadly, the issue of opioids use in the population along with its fatal outcomes seems never to stop. The American Food & Drug Asministation (FDA) requires, according to a …
The opioid epidemic: Is there a never ending sad story? Read more »
November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication …